Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
3201
Oruka Therapeutics
ORKA
$7.16B
| $773K | ﹤0.01% |
75,333
+750
| +1% | +$9.35K |
|
3202
BW LPG
BWLP
$3.38B
| $773K | ﹤0.01% |
71,030
-1,475,047
| -95% | -$17.6M |
|
3203
Alpha and Omega Semiconductor
AOSL
$916M
| $773K | ﹤0.01% |
31,086
-39,093
| -56% | -$1.31M |
|
3204
Jack in the Box
JACK
$358M
| $772K | ﹤0.01% |
28,395
-68,123
| -71% | -$2.51M |
|
3205
Vanda Pharmaceuticals
VNDA
$304M
| $772K | ﹤0.01% |
168,093
-10,275
| -6% | -$47.9K |
|
3206
Willdan Group
WLDN
$1.29B
| $771K | ﹤0.01% |
18,932
-3,992
| -17% | -$148K |
|
|
ITOS
3207
DELISTED
iTeos Therapeutics
ITOS
| $770K | ﹤0.01% |
128,977
-3,917
| -3% | -$28.8K |
|
3208
Koppers
KOP
$874M
| $768K | ﹤0.01% |
27,412
-9,090
| -25% | -$273K |
|
3209
MoonLake Immunotherapeutics
MLTX
$1.4B
| $766K | ﹤0.01% |
19,599
+14,953
| +322% | +$644K |
|
3210
PUT
DaVita
DVA
$11.4B
| $765K | ﹤0.01% |
5,000
-50,000
| -91% | -$7.86M |
|
|
MLNK
3211
DELISTED
MeridianLink
MLNK
| $763K | ﹤0.01% |
41,179
-15,935
| -28% | -$308K |
|
3212
The RMR Group
RMR
$346M
| $756K | ﹤0.01% |
45,429
-8,313
| -15% | -$153K |
|
3213
ARK Genomic Revolution ETF
ARKG
$1.78B
| $755K | ﹤0.01% |
36,375
+14,375
| +65% | +$361K |
|
3214
Costamare
CMRE
$1.74B
| $755K | ﹤0.01% |
76,693
+11,871
| +18% | +$131K |
|
3215
OneSpan
OSPN
$624M
| $754K | ﹤0.01% |
49,445
-23,905
| -33% | -$426K |
|
3216
Climb Global Solutions
CLMB
$532M
| $753K | ﹤0.01% |
27,204
-8,384
| -24% | -$259K |
|
3217
Shoals Technologies Group
SHLS
$1.37B
| $753K | ﹤0.01% |
226,772
-74,138
| -25% | -$308K |
|
|
CMRX
3218
DELISTED
Chimerix, Inc.
CMRX
| $753K | ﹤0.01% |
88,435
+85,935
| +3,437% | +$474K |
|
|
ACCD
3219
DELISTED
Accolade Inc
ACCD
| $753K | ﹤0.01% |
107,809
-43,684
| -29% | -$292K |
|
3220
ArriVent BioPharma
AVBP
$1.4B
| $750K | ﹤0.01% |
40,583
-12,916
| -24% | -$316K |
|
3221
Hudbay
HBM
$11.8B
| $750K | ﹤0.01% |
98,864
+5,578
| +6% | +$45.4K |
|
3222
Cass Information Systems
CASS
$750M
| $747K | ﹤0.01% |
17,269
-6,753
| -28% | -$287K |
|
|
PLYA
3223
DELISTED
Playa Hotels & Resorts
PLYA
| $747K | ﹤0.01% |
56,029
-46,756
| -45% | -$607K |
|
|
ADAM
3224
Adamas Trust
ADAM
$907M
| $746K | ﹤0.01% |
114,927
-44,555
| -28% | -$284K |
|
3225
ProFrac Holding
ACDC
$958M
| $739K | ﹤0.01% |
97,382
+63,973
| +191% | +$491K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.